PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(02): 116-118
DOI: 10.4103/0971-5851.180143
CASE REPORT

Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus

Shalabh Arora
Department of Medical Oncology, Christian Medical College Hospital, Vellore, Tamil Nadu, India
,
Rajendra Akhil
Department of Medical Oncology, Christian Medical College Hospital, Vellore, Tamil Nadu, India
,
Raju Titus Chacko
Department of Medical Oncology, Christian Medical College Hospital, Vellore, Tamil Nadu, India
,
Renu George
Department of Dermatology, Venereology and Leprosy, Christian Medical College Hospital, Vellore, Tamil Nadu, India
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
  als PDF herunterladen Lizenzen und Reprints

Abstract

Mammalian target of rapamycin inhibitor everolimus is a novel agent used in endocrine therapy resistant hormone receptor positive metastatic breast cancer. Its use has been associated with clinically significant improvement in the otherwise dismal outcomes of this subset of patients. Rash is a common adverse effect associated with everolimus. However, Hand-foot syndrome is an uncommon toxicity with the use of this drug. We report a case of Grade 3 hand-foot syndrome following institution of everolimus therapy and describe its successful management.

Keywords

Breast cancer - everolimus - hand-foot syndrome - mammalian target of rapamycin inhibitors - palmar-plantar erythrodysesthesia


Publikationsverlauf

Artikel online veröffentlicht:
12. Juli 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331S-6S.
  • 2 Efeyan A, Sabatini DM. mTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol 2010;22:169-76.
  • 3 Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94.
  • 4 Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003;9:511S-5S.
  • 5 Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 2012;30:2718-24.
  • 6 Massarweh S, Romond E, Black EP, Van Meter E, Shelton B, Kadamyan-Melkumian V, et al. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Res Treat 2014;143:325-32.
  • 7 Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013;30:870-84.
  • 8 Gilbar P. Palmar-plantar erythrodysesthesia. J Oncol Pharm Pract 2003;9:137-50.
  • 9 Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
  • 10 Ramirez-Fort MK, Case EC, Rosen AC, Cerci FB, Wu S, Lacouture ME. Rash to the mTOR Inhibitor Everolimus: Systematic Review and Meta-Analysis. Am J Clin Oncol 2012;37:266-71.
  • 11 Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010;116:4256-65.